Prolonging remission with rituximab maintenance therapy.

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Indolent non-Hodgkin's lymphoma (iNHL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are B-cell malignancies.
• Prolonging remission in these diseases is a clinical challenge.
• Rituximab, an anti-CD20 monoclonal antibody, has shown efficacy in B-cell lymphomas.

Purpose of the Study:

• To evaluate the efficacy of maintenance rituximab therapy in patients with previously untreated indolent non-Hodgkin's lymphoma.
• To assess the impact of maintenance rituximab on response rates and progression-free survival.
• To confirm findings from phase II trials in a randomized phase III setting.

Main Methods:

• Phase II trial: Rituximab as first-line therapy followed by maintenance in previously untreated iNHL.
• Phase II trial: Similar approach in previously untreated CLL/SLL.
• Phase III trial (Swiss Group for Clinical Cancer Research): Randomized patients with follicular non-Hodgkin's lymphoma to observation or maintenance rituximab after initial treatment.

Main Results:

• Phase II iNHL trial: Overall response rate increased from 47% to 73% with maintenance; median progression-free survival (PFS) was 37 months.
• Phase II CLL/SLL trial: Improved response rates and median PFS of 19 months with maintenance.
• Phase III trial: Median event-free survival (EFS) was significantly longer in the maintenance rituximab group (23 months) compared to observation (12 months; P = .02).
• Toxicity of maintenance rituximab was minimal across all trials.

Conclusions:

• Maintenance rituximab therapy prolongs remission duration and improves event-free survival in patients with indolent non-Hodgkin's lymphoma.
• The observed benefits in phase II trials were confirmed in a randomized phase III study.
• Ongoing trials are investigating optimal schedules, use after combination therapies, and efficacy in other B-cell neoplasms.